Agilent Technologies (NYSE:A) Price Target Lowered to $141.00 at UBS Group

Agilent Technologies (NYSE:AFree Report) had its price target reduced by UBS Group from $155.00 to $141.00 in a research report released on Thursday morning, Benzinga reports. UBS Group currently has a neutral rating on the medical research company’s stock.

A number of other equities research analysts have also weighed in on A. Bank of America restated a neutral rating and set a $134.00 price objective (down previously from $145.00) on shares of Agilent Technologies in a research note on Thursday. Stifel Nicolaus decreased their price target on shares of Agilent Technologies from $163.00 to $151.00 and set a buy rating for the company in a research report on Thursday. Citigroup upped their price target on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a neutral rating in a report on Wednesday, February 28th. Barclays raised their price objective on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an underweight rating in a report on Wednesday, April 10th. Finally, Evercore ISI cut their target price on shares of Agilent Technologies from $145.00 to $126.00 and set an in-line rating on the stock in a research note on Thursday. One analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $137.19.

Read Our Latest Stock Analysis on A

Agilent Technologies Price Performance

Shares of A stock opened at $130.41 on Thursday. The firm has a fifty day simple moving average of $143.45 and a 200-day simple moving average of $137.48. The company has a market capitalization of $38.22 billion, a PE ratio of 30.83, a price-to-earnings-growth ratio of 3.70 and a beta of 1.13. Agilent Technologies has a twelve month low of $96.80 and a twelve month high of $155.35. The company has a current ratio of 2.15, a quick ratio of 2.04 and a debt-to-equity ratio of 0.34.

Agilent Technologies (NYSE:AGet Free Report) last posted its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.03. The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The firm’s revenue for the quarter was down 8.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.27 EPS. Equities research analysts anticipate that Agilent Technologies will post 5.2 earnings per share for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be paid a dividend of $0.236 per share. The ex-dividend date is Tuesday, July 2nd. This represents a $0.94 dividend on an annualized basis and a yield of 0.72%. Agilent Technologies’s payout ratio is currently 22.22%.

Insiders Place Their Bets

In related news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Agilent Technologies news, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the transaction, the chief executive officer now owns 253,909 shares in the company, valued at approximately $38,086,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Heidi Fields sold 1,658 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the transaction, the director now directly owns 54,976 shares of the company’s stock, valued at approximately $7,935,235.84. The disclosure for this sale can be found here. Insiders have sold 61,610 shares of company stock valued at $9,220,333 over the last three months.

Institutional Investors Weigh In On Agilent Technologies

Institutional investors have recently bought and sold shares of the stock. Lincoln National Corp increased its stake in Agilent Technologies by 7.8% during the 3rd quarter. Lincoln National Corp now owns 2,538 shares of the medical research company’s stock valued at $284,000 after buying an additional 184 shares during the period. Jump Financial LLC boosted its holdings in shares of Agilent Technologies by 48.0% in the third quarter. Jump Financial LLC now owns 10,381 shares of the medical research company’s stock valued at $1,161,000 after acquiring an additional 3,369 shares in the last quarter. Atria Investments Inc increased its stake in shares of Agilent Technologies by 17.0% during the third quarter. Atria Investments Inc now owns 10,908 shares of the medical research company’s stock valued at $1,220,000 after acquiring an additional 1,585 shares during the period. Barclays PLC raised its holdings in Agilent Technologies by 18.0% during the third quarter. Barclays PLC now owns 636,099 shares of the medical research company’s stock worth $71,129,000 after purchasing an additional 97,241 shares in the last quarter. Finally, Metis Global Partners LLC lifted its position in Agilent Technologies by 8.1% in the third quarter. Metis Global Partners LLC now owns 15,010 shares of the medical research company’s stock worth $1,678,000 after purchasing an additional 1,123 shares during the period.

Agilent Technologies Company Profile

(Get Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

See Also

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.